Adults and children aged 6 years and above: relief of nasal and eye symptoms associated with seasonal and chronic allergic rhinitis, relief of symptoms of chronic idiopathic urticaria.
Cetirizine, a metabolite of hydroxyzine, is a potent and selective antagonist of peripheral histamine H-receptors1. In addition, it has antiallergic activity, inhibits the influx of cells in the late phase of the inflammatory reaction, eosinophils, to the skin and conjunctiva. It inhibits the reaction leading to the formation of wheals and redness. It relieves the symptoms of rhinitis and does not affect lung function. The maximum steady-state cetirizine concentration occurs within 1.0 ± 0.5 hours after oral administration. Cetirizine is bound to plasma proteins in approximately 93 ± 0.3%. The first pass metabolism is not significantly affected. About 2/3 of the dose is excreted unchanged in the urine. Final T0,5 is about 10 hours; it is shorter in children.
Contraindications:
Hypersensitivity to cetirizine, hydroxyzine, other piperazine derivatives or to any of the excipients. Severe renal impairment with creatinine clearance <10 ml / min. Due to the lactose content, tabl. powl. do not use in patients with galactose intolerance, Lapp lactase deficiency or malabsorption of glucose-galactose.
Precautions:
It is not recommended for use in children <6 years of age, because this form of the drug does not allow for a suitable dose adjustment. Use with caution in patients with renal insufficiency (dose modification recommended), epilepsy or risk of seizures and in combination with alcohol.
Pregnancy and lactation:
Animal studies do not indicate any harmful effects of cetirizine on pregnancy or on the health of the fetus and / or newborn. Caution should be exercised when cetirizine is administered to pregnant or breastfeeding women (the drug is excreted in human milk).
Side effects:
The following may occur: drowsiness, fatigue, headache and dizziness, abdominal pain, dry mouth, nausea, sore throat. In children with a frequency of ≥1%, diarrhea, drowsiness, rhinitis, and tiredness were observed. In addition, the following side effects have been reported post-marketing - uncommon: agitation, paresthesia, diarrhea, pruritus, rash, asthenia, malaise; rare: hypersensitivity reactions, aggressive behavior, confusion, depression, hallucinations, insomnia, convulsions, tachycardia, abnormal liver function (increased transaminases, alkaline phosphatase, GGT, increased bilirubin), urticaria, edema, weight gain; very rare: thrombocytopenia, anaphylactic shock, tics, taste disturbances, syncope, tremor, dystonia, dyskinesia, accommodation disorder, blurred vision, eyeball rotation, angioneurotic edema, drug eruption, painful or difficult urination, involuntary urination; frequency unknown: amnesia, memory problems.
Dosage:
Orally. Adults and children> 12 years: 10 mg (1 table) once a day; children 6-12 years: 5 mg (1/2 times table) 2 times a day.Special groups of patients. In patients with hepatic impairment and in the elderly, no dosage adjustment is necessary. In adult patients with renal insufficiency, the dosage depends on the creatinine clearance (CCr) - CCr = 50-79 ml / min: 10 mg once a day; CCr = 30-49 ml / min: 5 mg once a day; CCr <30 ml / min: 5 mg every other day; CCr <10 ml / min, dialysis patients: use contraindicated. In children with renal impairment, the dose should be determined individually based on the creatinine clearance, age and weight of the patient.Way of giving. Table. The powl can be divided into two equal doses along the incision.